Mural Oncology

1.12
-0.11 (-8.94%)
At close: Apr 04, 2025, 3:59 PM
1.14
2.12%
After-hours: Apr 04, 2025, 07:50 PM EDT

Company Description

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer.

The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.

It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs.

The company was incorporated in 2017 and is based in Dublin, Ireland.

As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Mural Oncology
Mural Oncology logo
Country IE
IPO Date Nov 16, 2023
Industry Biotechnology
Sector Healthcare
Employees 116
CEO Caroline J. Loew Ph.D.

Contact Details

Address:
10 Earlsfort Terrace
Dublin,
IE
Website https://www.muraloncology.com

Stock Details

Ticker Symbol MURA
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001971543
CUSIP Number n/a
ISIN Number IE000LK2BOB4
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Caroline J. Loew Ph.D. President, Chief Executive Officer & Director
Adam D. Cutler B.A. Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Maiken Keson-Brookes Chief Legal Officer
Dr. Vicki L. Goodman M.D. Chief Medical Officer
Justin Levine Head of Human Resources & Vice President of Human Resources

Latest SEC Filings

Date Type Title
Mar 25, 2025 8-K Current Report
Mar 11, 2025 8-K Current Report
Mar 11, 2025 424B5 Filing
Mar 11, 2025 S-8 Filing
Mar 11, 2025 10-K Annual Report
Mar 11, 2025 8-K Current Report
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing